Inactive Matrix Gla Protein Is Causally Related to Adverse Health Outcomes. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Liu, Yan-Ping; Gu, Yu-Mei; Thijs, Lutgarde; Knapen, Marjo H.J.; Salvi, Erika; Citterio, Lorena; Petit, Thibault; Carpini, Simona Delli; Zhang, Zhenyu; Jacobs, Lotte; Jin, Yu; Barlassina, Cristina; Manunta, Paolo; Kuznetsova, Tatiana; Verhamme, Peter; Struijker-Boudier, Harry A.; Cusi, Daniele; Vermeer, Cees; Staessen, Jan A.
• Is Part Of: Hypertension. Volume 65:Issue 2(2015:Feb.)
• Publication Date: 2015-02
• Subjects: Hypertension -- Periodicals; Hypertension -- Treatment -- Periodicals; 616.132005
• DOI: 10.1161/HYPERTENSIONAHA.114.04494
• Languages: English
• ISSNs: 0194-911X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>Matrix Gla-protein is a vitamin K–dependent protein that strongly inhibits arterial calcification. Vitamin K deficiency leads to production of inactive nonphosphorylated and uncarboxylated matrix Gla protein (dp–ucMGP). The risk associated with dp–ucMGP in the population is unknown. In a Flemish population study, we measured circulating dp–ucMGP at baseline (1996–2011), genotyped <italic>MGP</italic>, recorded adverse health outcomes until December 31, 2012, and assessed the multivariable-adjusted associations of adverse health outcomes with dp–ucMGP. We applied a Mendelian randomization analysis using <italic>MGP</italic> genotypes as instrumental variables. Among 2318 participants, baseline dp–ucMGP averaged 3.61 μg/L. Over 14.1 years (median), 197 deaths occurred, 58 from cancer and 70 from cardiovascular disease; 85 participants experienced a coronary event. The risk of death and non-cancer mortality curvilinearly increased (<italic>P</italic>⩽0.008) by 15.0% (95% confidence interval, 6.9–25.3) and by 21.5% (11.1–32.9) for a doubling of the nadir (1.43 and 0.97 μg/L, respectively). With higher dp–ucMGP, cardiovascular mortality log-linearly increased (hazard ratio for dp–ucMGP doubling, 1.14 [1.01–1.28]; <italic>P</italic>=0.027), but coronary events log-linearly decreased (0.93 [0.88–0.99]; <italic>P</italic>=0.021). dp–ucMGP levels were associated (<italic>P</italic>⩽0.001) with <italic>MGP</italic> variants <italic>rs2098435</italic>, <italic>rs4236</italic>, and <italic>rs2430692.</italic> For non-cancer mortality and coronary events (<italic>P</italic>⩽0.022), but not for total and cardiovascular mortality (<italic>P</italic>≥0.13), the Mendelian randomization analysis suggested causality. Higher dp–ucMGP predicts total, non-cancer and cardiovascular mortality, but lower coronary risk. For non-cancer mortality and coronary events, these associations are likely causal.</p> </sec> </abstract>